Company: CERO
Filing Date: 2025-01-03
Form Type: 424B3
Source: 0001213900-25-000475
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-03
Form: 424B3
Chunk 3
---
1 (File No. 333-283492) relating to the resale of shares that
the Company may require an investor to purchase pursuant to a committed equity financing facility (the “Equity Line”) were
declared effective by the Securities and Exchange Commission.

Warrant Exercises

From December 6, 2024 through
December 23, 2024, holders of Preferred Warrants exercised an aggregate of 962 Preferred Warrants for shares of Series A Preferred Stock
with an aggregate stated value of $962,000, at an exercise price of $800 per share (the “Warrant Exercises”), reflecting the
20% original issue discount applicable to the issuance of shares of Series A Preferred Stock relative to the stated value thereof. The
Company received an aggregate of $769,600 of cash proceeds from the Warrant Exercises. As the PIPE Registration Statement cured a triggering
event under the terms of the Series A Preferred Stock pursuant to which the holders thereof have the right to convert their shares of
Series A Preferred Stock through the alternate conversion procedures set forth in such terms until 20 trading days after such cure, the
Series A Preferred Stock is convertible at a conversion rate equal to 125% of the stated value thereof divided by the alternate conversion
price thereof, which fluctuates daily.

Preferred Stock Conversions

From December 6, 2024 through
December 26, 2024, holders of shares of Series A Preferred Stock, including holders of shares issued pursuant to the Warrant Exercises,
converted an aggregate of approximately 2,600 shares of Series A Preferred Stock and 213 shares of Series B Preferred Stock into an aggregate
of approximately 68 million shares of Common Stock.

Warrant Issuances

On December 23, 2024, the
Company issued warrants to purchase an aggregate of 8,405,942 shares of Common Stock, with an exercise price of $0.0561 per share, which
was the closing price of the Common Stock on Nasdaq on December 20, 2024, to certain institutional investors as a condition to the Warrant
Exercises thereby. Such shares were issued in reliance upon the exemption from registration set forth in Section 4(a)(2) of the Securities
Act of 1933, as amended.

Equity Line Issuances

From December 6, 2024 through
December 30, 2024, the Company has issued an aggregate of approximately 16 million shares of Common Stock pursuant to the Equity Line